Ausgabe 9/2010
Inhalt (5 Artikel)
Current Opinion
Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins
Hesham S. Al-Sallami, Michael A. Barras, Bruce Green, Stephen B. Duffull
Original Research Article
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
Gezim Lahu, Andreas Hünnemeyer, Edgar Diletti, Martin Elmlinger, Peter Ruth, Karl Zech, Nigel McCracken, Axel Facius
Original Research Article
Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
Angelika Weil, Paul Martin, Robert Smith, Stuart Oliver, Peter Langmuir, Jessica Read, Karl-Heinz Molz
Original Research Article
Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans
Zvi Teitelbaum, Thierry Lave, Jan Freijer, Adam F. Cohen